Amyloid-Targeted Therapies (ATTs) and Their Adverse Effects - What Should Geriatricians Know

Role of Fluid Biomarkers in the Diagnosis of Alzheimer’s Disease

Join Dr. Michael Harper, Professor of Medicine at the University of California, San Francisco and Dr. Cindy Carlsson , Professor of Medicine Geriatrics at the University of Wisconsin School of Medicine and Public Health and staff physician at the Madison VA Hospital Geriatric Research, Education and Clinical Center (GRECC), Madison VA Memory Assessment Clinic, as they the role of fluid biomarkers in the Diagnosis of Alzheimer’s Disease. To view a transcript click here [https://www.buzzsprout.com/2540871/episodes/18359015], then select the transcript tab.

Amyloid-Targeted Therapies (ATTs) and Their Adverse Effects - What Should Geriatricians Know

Join Dr. Michael Harper, Professor of Medicine at the University of California, San Francisco and Dr. Daniel Parker, Associate Professor of Medicine in the Division of Geriatrics, Assistant Professor of Neurology and Medical Director at the Duke Memory Disorders Clinic at Duke University School of Medicine, as they discuss Amyloid-Targeted Therapies (ATTs) and Their Adverse Effects. To view a transcript click here [https://www.buzzsprout.com/2540871/episodes/18028206] then select the transcript tab.

The Role of Neuroimaging in Diagnosis of Alzheimer Disease

Join Dr. Michael Harper, Professor of Medicine at the University of California, San Francisco and Dr. Kyra O'Brien Assistant Professor of Neurology at the Hospital of the University of Pennsylvania who, co-authored the module titled The Role of Neuroimaging in Diagnosis of Alzheimer Disease along with Jason Karlawish, MD, Professor of Medicine, medical ethics and health policy, and neurology at the University of Pennsylvania Perelman School of Medicine and Co-Associate Director of the Alzheimer’s Disease Research Center, and Co-Director of the Penn Memory Center. To view a transcript click here [https://www.buzzsprout.com/2540871/episodes/18027863] then select the transcript tab.

How to Talk to Patients and Families About Monoclonal Antibody Treatments for Alzheimer Disease (What Matters)

Join Dr. Michael Harper, Professor of Medicine at the University of California, San Francisco; Dr. Halima Amjad, Associate Professor in the Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine and Dr. Lolita Nidadavolu, Assistant Professor in the Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, as they discuss How to Talk to Patients and Families About Monoclonal Antibody Treatments for Alzheimer Disease (What Matters). To view a transcript click here [https://www.buzzsprout.com/2540871/episodes/18022012]then select the transcript tab.

Evidence Review of FDA-Approved Monoclonal Antibody Treatments

Join Dr. Michael Harper, Professor of Medicine at the University of California, San Francisco and Dr. Eric Widera of  Professor of Clinical Medicine, Division of Geriatrics at UCSF and the Director of Hospice & Palliative Care at San Francisco VA Medical Center who, co-authored the module titled Evidence Review of FDA-Approved Monoclonal Antibody Treatments along with Kaitlin Willham, MD, Outpatient Geriatrics Clinic Medical Director at the San Francisco VA and Associate Professor of Medicine, at UCSF Division of Geriatrics. To view a transcript click here [https://www.buzzsprout.com/2540871/episodes/18018317] then select the transcript tab.